Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
27.15
52.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Dizal Jiangsu Pharmaceutical Co Ltd
Total Liabilities
Dizal Jiangsu Pharmaceutical Co Ltd
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
|
Total Liabilities
¥647.8m
|
CAGR 3-Years
85%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Liabilities
¥16B
|
CAGR 3-Years
13%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Liabilities
¥3B
|
CAGR 3-Years
47%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Total Liabilities
¥1.6B
|
CAGR 3-Years
27%
|
CAGR 5-Years
35%
|
CAGR 10-Years
12%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Total Liabilities
¥23.3B
|
CAGR 3-Years
32%
|
CAGR 5-Years
39%
|
CAGR 10-Years
62%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Total Liabilities
¥504.4m
|
CAGR 3-Years
72%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
Dizal Jiangsu Pharmaceutical Co Ltd
Glance View
Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 328 full-time employees. The company went IPO on 2021-12-10. The firm focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The firm is still in the R&D stage.
See Also
What is Dizal Jiangsu Pharmaceutical Co Ltd's Total Liabilities?
Total Liabilities
647.8m
CNY
Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Total Liabilities amounts to 647.8m CNY.
What is Dizal Jiangsu Pharmaceutical Co Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
46%
Over the last year, the Total Liabilities growth was 100%. The average annual Total Liabilities growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 85% over the past three years , 46% over the past five years .
You don't have any saved screeners yet
